Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 415 shares of the firm’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $166.56, for a total transaction of $69,122.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
NYSE SYK opened at $168.13 on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $61.88 billion, a price-to-earnings ratio of 25.91, a price-to-earnings-growth ratio of 2.27 and a beta of 0.64. Stryker Co. has a 12-month low of $146.80 and a 12-month high of $179.84.
Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 25th. The medical technology company reported $1.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.01. Stryker had a net margin of 9.31% and a return on equity of 28.00%. The firm had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.26 billion. As a group, analysts anticipate that Stryker Co. will post 7.28 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date was Thursday, September 27th. Stryker’s payout ratio is 28.97%.
Several institutional investors have recently modified their holdings of SYK. Fundsmith Equity Fund L.P. acquired a new stake in shares of Stryker in the second quarter worth $931,542,000. FMR LLC lifted its stake in shares of Stryker by 24.0% in the second quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after buying an additional 1,032,333 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Stryker by 1,061.0% in the second quarter. Point72 Asset Management L.P. now owns 951,528 shares of the medical technology company’s stock worth $160,675,000 after buying an additional 869,568 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Stryker by 2.7% in the second quarter. BlackRock Inc. now owns 24,551,677 shares of the medical technology company’s stock worth $4,145,795,000 after buying an additional 646,505 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Stryker by 358.1% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 426,404 shares of the medical technology company’s stock worth $75,763,000 after buying an additional 333,316 shares during the last quarter. Institutional investors and hedge funds own 74.71% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Tuesday, October 30th. Oppenheimer set a $170.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Friday, October 26th. Barclays assumed coverage on shares of Stryker in a report on Monday, October 15th. They set an “overweight” rating and a $198.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Stryker to $200.00 and gave the company an “overweight” rating in a report on Thursday, September 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $187.00 price target on shares of Stryker in a report on Wednesday, September 12th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $181.15.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/stryker-co-syk-vp-m-kathryn-fink-sells-415-shares.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: What is insider trading?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.